HVH-2930

HVH-2930 is an inhibitor for heat shock protein 90 (HSP90) . HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P9907) sensitive) and JIMT-1 (Trastuzumab (HY-P9907) resistant), with IC50 of 6.86 μM and 4.42 μM, through downregulation of HSP90 clients HER2, p-HER2, AKT, p-AKT, cyclin D1 and survivin. HVH-2930 exhibits antitumor efficacy in mouse models. HVH-2930 exhibits good pharmacokinetic characteristics in mice[1].

Product Specifications

CAS Number

[3034605-72-3]

UNSPSC

12352005

Target

Akt; EGFR; HSP; Survivin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hvh-2930.html

Purity

96.54

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=C(OC)C(C=CC(C)(C)O2)=C2C=C1)NC3=CC4=C(C=C3)C(C)=NN4CCC5CCN(C)CC5

Molecular Formula

C29H36N4O3

Molecular Weight

488.62

References & Citations

[1]La M T, et al. Discovery of Indazole Inhibitors for Heat Shock Protein 90 as Anti-Cancer Agents[J]. European Journal of Medicinal Chemistry, 2024: 116620.